Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Personalised Co. is a nutrition company on a mission to help as many people as possible reach their health and wellbeing goals by making supplements accessible and affordable. The company asserts that it provides personalised nutritional products to its consumers. Customers are required to take a quiz on the company's portal, based on which, the company's custom-built algorithm creates nutritionist-approved solutions tailored to the specific needs and goals of each customer. Personalised Co. has delivered 270,000 daily vitamin sachets till date. The company has also raised £192,000 from private investors and its first crowdfunding campaign in 2019. It achieved its milestone month in April 2020 earning £48,000 in revenue and delivering over 1,700 personalised vitamins and protein orders. The company will use the investment to level-up its operations, expand its product line and develop its companion-application.
days to go:
Expired
investment:
£401,417
Smartlands is a blockchain-based digital finance and investment ecosystem. It allows asset owners to turn an ownership right to a share of any asset, into a tradable digital token attributing it almost unlimited liquidity. In the UK, Smartlands is the first platform for crowdfunding investments that allows investors to use digital currencies alongside fiat currencies to raise capital. The platform boasts of a 16,000 strong community following with over 11,000 wallets opened since its inception. It has a reputed list of partners including Colliers International, CMS, Archax, UK Sotheby’s, and many more. They have been awarded the 'Best Crowdfunding Platform' at the 2020 FinTech Breakthrough Awards and have been featured in Yahoo Finance, Forbes, Coindesk, Benzinga, and Investors Chronicle to name a few. With the investment, the company will grow its internal engineering team and obtain the necessary licenses to move its business forward across Europe.
days to go:
Expired
investment:
£379,183
Alter Vego (AV) aims to create an extensive range of plant-based, customisable supplements. The company asserts that its production process is sustainable. It starts by creating a vegan protein base blend from ingredients such as pea, hemp, quinoa and brown rice that is ethically sourced and produced. It then develops daily sachets that contain Omega 3, B12, D3, K1, digestive enzymes, and probiotics to complement the base blend. AV argues that the sachets provide 100% of a user's Recommended Dietary Allowance (RDA) over any pre-mixed bulk blend. It aspires to become a contender in the global nutrition sector worth $702 billion. AV will use the investment for manufacturing and marketing its products across the UK.
days to go:
Expired
investment:
£46,455
Super U is a health food brand, creating great-tasting and nutritious superfood blends and providing a natural, innovative & convenient way of consuming superfoods, without costing the Earth. The company has 3500+ online consumers and, the social audience has risen to over 8,500 followers. Additionally, Super U has been a finalist for Start-Up Business of the Year and Health & Beauty Business of the Year 2019 - for the Great British Entrepreneur Awards. The funds will be used for growth, marketing and export strategies.
days to go:
Expired
investment:
£160,110
Nextfin is an FCA approved aggregation and rating portal for equity and debt crowdfunding investments.
AIM is shrinking, legacy stock markets are too expensive to maintain and do not serve the requirements of SMEs, banks are closing branches, lending less and are paying little or no interest to investors. As a result of this, there is a huge growth in equity crowdfunding and P2P lending which has seen the launch of hundreds of alternative lenders & platforms that has created a new c.£3bn marketplace, expanding at 66% p.a. There is no single portal or trusted ratings index for investors to compare on a like for like basis and no secondary market to facilitate exits.
* NextFin is the new trading name of Business Agent Ltd
The solution
NextFin aggregates equity and debt crowdfunding investments to create the alternative finance marketplace. This makes it easy for investors and lenders to find and compare opportunities by presenting all investment offerings in one place. With the addition of a free of charge ratings service investors will be able to view ratings of every equity crowdfunding pitch, every P2P site, and every equity crowdfunding site. NextFin’s technology will constantly track these companies and investments providing the investor real-time intelligence on which to base investment decisions. The platforms and entrepreneurs will be self-promoting and marketing their ratings driving thousands of visitors a month to the NextFin site, in the same way, businesses refer their potential clients to Trip Advisor and Trustpilot. There is an estimated 10 million website/platform visitors per month across the whole of the alternative finance market. NextFin is targeting to direct 5% of this highly profiled traffic to its platform from which it will earn between £5-£8 per click from advertisers and partners. In addition, an in-house brokerage service also earns between 1%-6% commissions on loan placements. A future revenue stream (not featured in the financials) will be developed once visitor traffic reaches critical mass. This will see Nextfin being able to realise the full value of its captured ratings data and visitor traffic by launching a secondary market, which is estimated to be a £5bn marketplace.
NextFin is raising £500k at a pre-money valuation of £2M to: • Develop P2P and Equity site ratings• Expand the management, infrastructure and marketing resource• Increase visitor traffic to 6m a year via rating referrals
Owing to the size of the market and rapid growth of the industry, enterprise valuations in alternative finance are based on visitor traffic, market share and registered users. Recently published valuations of companies with visitor traffic of over 6m per year are in excess of £70m. NextFin is the market-leading aggregator and has first-mover advantage. It has the potential to exceed these valuations because it is the whole of the market aggregator and is currently the only ratings service provider as it grows to achieve 500,000 visitors p.m.
days to go:
Expired
investment:
£274,057
